TRCT
CRVS icon

Tower Research Capital (TRC)’s Corvus Pharmaceuticals CRVS Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$137K Buy
9,362
+8,731
+1,384% +$139K ﹤0.01% 1928
2025
Q4 		$4.86K Sell
631
-1,856
-75% -$14.6K ﹤0.01% 4172
2025
Q3 		$18.3K Sell
2,487
-1,739
-41% -$8.9K ﹤0.01% 3389
2025
Q2 		$16.9K Buy
4,226
+1,227
+41% +$4.46K ﹤0.01% 3770
2025
Q1 		$9.54K Sell
2,999
-10,823
-78% -$51K ﹤0.01% 3763
2024
Q4 		$73.9K Buy
+13,822
New +$103K ﹤0.01% 2334
2024
Q3 		– Sell
-15,300
Closed -$27.8K – 5742
2024
Q2 		$27.8K Buy
15,300
+3,789
+33% +$7.06K ﹤0.01% 3544
2024
Q1 		$20.5K Buy
11,511
+3,008
+35% +$6.28K ﹤0.01% 2981
2023
Q4 		$15K Sell
8,503
-16,234
-66% -$23.7K ﹤0.01% 3846
2023
Q3 		$36.1K Buy
24,737
+4,194
+20% +$8.87K ﹤0.01% 2851
2023
Q2 		$47K Buy
20,543
+7,946
+63% +$16.5K ﹤0.01% 2633
2023
Q1 		$11K Sell
12,597
-121
-1% -$94 ﹤0.01% 4196
2022
Q4 		$11K Buy
12,718
+1,050
+9% +$929 ﹤0.01% 3799
2022
Q3 		$10K Buy
11,668
+2,335
+25% +$2.23K ﹤0.01% 4518
2022
Q2 		$9K Buy
9,333
+6,361
+214% +$7.8K ﹤0.01% 4542
2022
Q1 		$5K Sell
2,972
-14,592
-83% -$26.7K ﹤0.01% 5035
2021
Q4 		$42K Sell
17,564
-3,635
-17% -$14.1K ﹤0.01% 2898
2021
Q3 		$102K Buy
21,199
+13,545
+177% +$40.1K ﹤0.01% 2384
2021
Q2 		$20K Sell
7,654
-35,132
-82% -$96.7K ﹤0.01% 3875
2021
Q1 		$132K Buy
42,786
+41,890
+4,675% +$151K ﹤0.01% 2347
2020
Q4 		$3K Sell
896
-5,554
-86% -$22.4K ﹤0.01% 4784
2020
Q3 		$26K Buy
6,450
+4,596
+248% +$18.4K ﹤0.01% 3772
2020
Q2 		$5K Buy
1,854
+1,654
+827% +$4.89K ﹤0.01% 4264
2020
Q1 		$0 Buy
+200
New +$812 ﹤0.01% 3163
2019
Q4 		– Sell
-2,147
Closed -$6K – 3663
2019
Q3 		$6K Buy
+2,147
New +$9.01K ﹤0.01% 3207
2019
Q2 		– Sell
-408
Closed -$2K – 3767
2019
Q1 		$2K Sell
408
-10,402
-96% -$43.9K ﹤0.01% 3388
2018
Q4 		$40K Buy
10,810
+9,140
+547% +$62.3K ﹤0.01% 1428
2018
Q3 		$14K Buy
1,670
+137
+9% +$1.37K ﹤0.01% 2549
2018
Q2 		$17K Sell
1,533
-2,100
-58% -$23.4K ﹤0.01% 2518
2018
Q1 		$42K Buy
3,633
+2,114
+139% +$20K ﹤0.01% 1768
2017
Q4 		$16K Sell
1,519
-748
-33% -$9.58K ﹤0.01% 2219
2017
Q3 		$37K Sell
2,267
-4,304
-65% -$59.5K ﹤0.01% 2241
2017
Q2 		$80K Buy
+6,571
New +$70.1K 0.01% 566
2017
Q1 		– Sell
-1,427
Closed -$21K – 3172
2016
Q4 		$21K Buy
+1,427
New +$21.7K ﹤0.01% 2080
2016
Q3 		– Sell
-3,455
Closed -$49K – 3741
2016
Q2 		$49K Buy
3,455
+411
+14% +$5.55K ﹤0.01% 1565
2016
Q1 		$44K Buy
+3,044
New +$43.7K 0.01% 841

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Tower Research Capital (TRC)'s CRVS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Corvus Pharmaceuticals (CRVS) stake by 1,384% in Q1 2026, buying an estimated $139K and bringing the position to 9,362 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

Tower Research Capital (TRC) first reported a position in CRVS in Q1 2016 and has held it in 36 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Tower Research Capital (TRC) held 9,362 shares of Corvus Pharmaceuticals worth $137K as of Q1 2026.
  • Tower Research Capital (TRC) bought 8,731 Corvus Pharmaceuticals shares in Q1 2026, an estimated $139K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1928 holding.
  • Tower Research Capital (TRC) first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 36 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.